Beriplex® P/N (Human prothrombin complex) product information

Description

- Beriplex® P/N is a lyophilized plasma protein preparation containing all the essential vitamin K dependent human coagulation factors (Factors II, VII, IX and X) and the thrombo-inhibitor proteins C and S.
- It is available in one formulation: Beriplex® P/N 500. Factor IX is considered the lead factor for the potency of the preparation.

Composition

- Contains all vitamin K-dependent coagulation factors (II, VII, IX and X) and thromboinhibitor proteins C and S (Table 1).
- Beriplex® P/N also contains the following non-medicinal ingredients: Heparin, human antithrombin III, human albumin, sodium chloride, sodium citrate and HCl or NaOH in small amount for pH adjustment.

Formulation and presentation

- A lyophilised powder in a single use vial available in 500 IU.
- It is supplied with a solvent (water) to allow for injection.
- The total protein content of a 500 IU vial of Beriplex® P/N is 120–280 mg of reconstituted solution.
- Each Beriplex® P/N pack contains:
    - One colourless glass vacuum vial containing dried substance
    - One colourless glass vial of solvent (20 mL Sterile Water for Injection, Ph.Eur.)
    - One transfer device (Mix2Vial™* - a needle-free transfer device).

Table 1: List of medicinal ingredients in Beriplex® P/N

Medicinal ingredients	Beriplex® P/N 500
Factor II	**380-800 IU/vial**
Factor VII	**200-500 IU/vial**
Factor IX	**400-620 IU/vial**
Factor X	**500-1020 IU/vial**
Protein C	**420-820 IU/vial**
Protein S	**240-680 IU/vial**

Indications

- Beriplex® P/N (Human prothrombin complex) is indicated in adults for the treatment of bleeding and perioperative prophylaxis of bleeding in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required.

- Beriplex® P/N can be used for the treatment of bleeding and perioperative prophylaxis of bleeding in congenital deficiency of any of the vitamin K dependent coagulation factors only if purified specific coagulation factor product is not available. No adequate study in subjects with congenital deficiency is available.

Contraindications

- Known hypersensitivity to any of the components of the product.
- Risk of thrombosis, angina pectoris, recent myocardial infarction (exception: lifethreatening haemorrhages following overdosage of oral anticoagulants, and before induction of a fibrinolytic therapy).
- In the case of disseminated intravascular coagulation, prothrombin complex-preparations may only be applied after termination of the consumptive state.
- Known history of heparin-induced thrombocytopenia.

Serious Warnings and Precautions

- The use of prothrombin complex concentrates is associated with the risk of thrombosis. Although a rare event, cases of thrombosis have been observed in conjunction with treatment with Beriplex® P/N.

Adverse events

- In clinical trials Beriplex® P/N was well tolerated, only 2 adverse events were assessed as related to the product (pulmonary embolism and laboratory test abnormal).

Dosing

The amount and the frequency of administration should be calculated on an individual patient basis. Dosage intervals must be adapted to the different circulating half-lives of the respective coagulation factors in the prothrombin complex. The dose will depend on the International Normalised Ratio (INR) before treatment and the targeted INR. In the following table approximate doses (ml/kg b.w.) of the reconstituted product and IU of Factor IX/kg b.w. required for normalisation of INR (e.g. ≤ 1.3) at different initial INR levels are given.

Initial INR	2.0 - 3.9	4.0 - 6.0	> 6.0
Approximate dose ml/kg b.w.	1	1.4	2
Approximate dose IU (Factor IX)/kg b.w.	25	35	50

It is recommended that the maximum single dose should not exceed 5000 IU of factor IX.

Administration

The reconstituted solution should be administered intravenously (not more than 3 IU/kg/min, max. 210 IU/min, approximately 8 ml/min).

Reconstitution

Please refer to product monograph for instructions.

Storage and stability

When stored at room temperature, up to + 25°C, Beriplex® P/N is stable for the period indicated by the expiration date on its label. The shelf life of Beriplex® P/N is 36 months. **Avoid freezing**, which may damage the solvent container. Keep Beriplex® P/N in its box during storage.

For complete risk / benefit profile as well as the full prescribing information of Beriplex® P/N, please refer to the current Product Monograph / Prescribing Information, available on our website at www.cslbehring.ca.

References:

Product monograph Beriplex® P/N (Human prothrombin complex), Nov 5, 2010

Data on file CSL Behring Canada

CSL Behring Canada Inc., 55, rue Metcalfe St., Suite 1460, Ottawa, ON, K1P 6L5, Canada. BpxFS-001, 2011.